loi
`
`5228320
`
`A
`
`IN !!1 "III
`
`II i!
`
`in
`
`i
`
`* 5 2 2 8 3 2 0 *
`
`iiii
`* A *
`
`Menostar (Berlex) 06/08/2004 Approval [Postmenopausal
`Osteoporosis]: Approval Letter; Final Labeling
`
`This document was provided by: FOI Services, Inc
`704 Quince Orchard Road • Suite 275
`Gaithersburg MD 20878-1751 USA
`Phone:
`301-975-9400
`Fax:
`301-975-0702
`infofoi@foiservices.com
`Email:
`
`Do you need additional U.S. Government information?
`
`Since 1975. FOI Services, Inc has specialized in acquiring government files using the Freedom of Information Act.
`We have millions of pages of unpublished documentation already on file and available for immediate delivery.
`
`Many of the documents you need are available for immediate downloading at:
`www. foiservices. com
`
`Unless specified otherwise, all of FOI Services' documents have been released by the U.S. Government under the provisions of the
`Freedom of Information Act and are therefore available to the general public. FOI Services, Inc. does not guarantee the accuracy of
`any of the information in these documents; the documents will be faithful copies of the information supplied to FOI Services. Inc.
`
` 
`

 
`0001
`
`MYLAN - EXHIBIT 1017
`
`

`

`CENTER FOR DRUG EVALUATION AND RESEARCH
`
`Approval Package for:
`
`APPLICA TION NUMBER:
`
`21-674
`
`Trade Name: Menostar
`
`Generic Name:
`
`Sponsor:
`
`Berlex Laboratories
`
`Approval Date: June 8, 2004
`
`Indications:
`
`Provides for the use of Menostar for the prevention of
`postmenopausal osteoporosis
`
`0002 
`
`

`

`CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`APPLICA TION NUMBER:
`21-674
`
`CONTENTS
`
`Reviews / Information Included in this NDA Review.
`x
`
`Approval Letter
`Approvable Letter 1
`Approvable Letter 2
`Final Printed Labeling
`Medical Review(s)
`Chemistry Review(s)
`EA/FONSI
`Pharmacology Review(s)
`Statistical Review(s)
`'
`Microbiology Review(s)
`Clinical Pharmacology/ Biopharmaceutics Review(s)
`Administrative/Correspondence Document(s)
`
`-X
`X
`X
`
`X
`X
`
`X
`X
`
`0003 
`
`

`

`CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`APPLICA TION NUMBER:
`21-674
`
`APPROVAL LETTER
`
`0004 
`
`

`

`I
`
`**•»«
`
`Y* DEPARTMENT OF HEALTH & HUMAN SERVICES
`
`Public Health Service
`Food and Drug Administration
`Rockvillo, MD 20857
`
`NDA 21-674
`
`Berlex Laboratories Inc.
`Attention: Geoffrey Millington
`Manager, Drug Regulatory Affairs
`340 Changebridge Road; P.O. Box 1000
`Montville, NJ 07045-1000
`
`Dear Mr. Millington:
`
`Please refer to your new drug application (NDA) dated August 7,2003, received August 8, 2003,
`submitted under section 505b of the Federal Food, Drug, and Cosmetic Act for Menostar (estradiol
`transdermal system).
`
`We acknowledge receipt of your submissions dated October 7, November 14, December 17,2003 and
`March 15, May 4, 12, 14, and June 2, and 8 (2 submissions), 2004.
`
`This new drug application provides for the use of Menostar (estradiol transdermal system) for prevention
`of postmenopausal osteoporosis.
`
`We have completed our review of this application and it is approved, effective on the date of this letter,
`for use as recommended in the agreed-upon labeling text and with the minor editorial changes to the foil
`pouches, containers and cartons listed below. The changes to the foil pouches must.be implemented
`before manufacture of batch no. 2.
`
`General Revisions to foil pouches, containers and cartons:
`
`1. Relocate the graphic that covers the beginning letter 'M' of the proprietaiy name so that it docs
`not interfere with the readability of the proprietary name.
`
`2. Increase, the prominence of the established name and strength, so that they are at least one-half
`the size of the proprietary name.
`
`3. Eliminate the terminal zeros listed throughout the container labels and carton labeling since they
`could be misinterpreted (e.g., 1.0 as 10).
`
`.
`
`Specific Revision to the foil pouches (sample and trade):
`
`1. Include the route of administration on the principal display panel (e.g.. For Transdermal Use).
`
`0005 
`
`

`

`NDA 21-674
`Page 2
`
`Specific Revisions to Menostar Carton Labeling (4 systems, 6x4 systems, sample card):
`
`.
`
`1. Increase the prominence of the route of administration statement on the principal display panel.
`
`2. Revise the net quantity statement to read '4 Transdermal Systems', '6 Patient Packs each
`containing '4 Transdermal Systems' or' 1 Transdermal System', as appropriate.
`
`The final printed labeling (FPL) must be identical to the enclosed labeling for the package insert and the
`patient package insert and include the minor editorial revisions to the submitted labeling (foil pouch,
`containers and cartons, submitted May 14, 2004). We remind you of your agreement to make the
`labeling changes to the foil pouches before production of batch no. 2. These changes can be submitted
`as a CBE-0 labeling supplement, which must contain final printed labeling.
`
`These revisions are terms of the NDA approval. Marketing the product before making the revisions,
`exactly as stated, in the product's labeling may render the product misbranded and an unapproved new
`drug.
`
`The electronic labeling rule published December 11,2003, (68 FR 69009) requires submission of
`labeling content in electronic format effective June 8, 2004. For additional information, consult the
`following guidances for industry regarding electronic submissions: Providing Regulatory Submissions in
`Electronic Format - NDAs (January, 1999) and draft guidance Providing Regulatory Submissions in
`Electronic Format — Content of Labeling ((February 2004). The guidances specify labeling to be
`submitted in pdf format. To assist in our review, we request that labeling also be submitted in MS Word
`format. If formatted copies of all labeling pieces (i.e., package insert, patient package insert, container
`labels, and carton labels) are submitted electronically, labeling does not need to be submitted in paper.
`For administrative purposes, designate this submission "FPL for approved NDA 21-674." Approval of
`this submission by FDA is not required before the labeling is used.
`
`All applications for new active ingredients, new dosage forms, new indications, new routes of
`administration, and new dosing regimens are required to contain an assessment of the safety and
`effectiveness of the product ih pediatric patients unless this requirement is waived or deferred. We are
`waiving the pediatric study requirement for this application.
`
`In addition, submit three copies of the introductory promotional materials that you propose to use for this
`product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this
`division and two copies of both the promotional materials and the package insert directly to:
`
`Division of Drug Marketing, Advertising,
`and Communications, HFD-42
`Food and Drug Administration
`5600 Fishers Lane
`Rockville, MD 20857
`
`We remind you that you must comply with reporting requirements for an approved NDA (21 CFR
`314.80 and 314.81).
`
`0006 
`
`

`

`NDA 21-674
`Page 3
`
`All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field
`alerts, annual reports, supplements, and other submissions should be addressed to the original
`NDA 20-375 for this drug product, not to this NDA. In the future, do not make submissions to
`this NDA except for the final printed labeling requested above.
`
`If you have any questions, call Pat Madara, Regulatory Project Manager, at (301) 827-6416.
`
`Sincerely,
`
`{See appended electronic signature page}
`
`David G. Orloff, M.D.
`Director
`Division of Metabolic and Endocrine Drug Products
`Office of Drug Evaluation 11
`Center for Drug Evaluation and Research
`
`Enclosure:
`
`package insert
`patient package insert
`
`0007 
`
`

`

`CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`APPLICATION NUMBER:
`21-674
`
`APPROVED LABELING
`
`0008 
`
`

`

`1
`
`Rx only
`PRESCRIBING INFORMATION Menostar™ (estradiol transdermal system)
`ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
`
`Close clinical surveillance of all women taking estrogens is important. Adequate
`diagnostic measures, including endometrial sampling when indicated, should be
`undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring
`abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens
`results in a different endometrial risk profile than synthetic estrogens at equivalent
`estrogen doses. (See WARNINGS, Malignant neoplasms, Endometrial cancer.)
`
`CARDIOVASCULAR AND OTHER RISKS
`
`Estrogens with and without progestins should not be used for the prevention of
`cardiovascular disease. (See WARNINGS, Cardiovascular disorders.)
`
`The Women's Health Initiative (WHI) study reported increased risks of myocardial
`infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in
`postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral
`conjugated estrogens (CE 0.625mg) combined with medroxyprogesterone acetate (MPA
`2.5mg) relative to placebo (see CLINICAL PHARMACOLOGY, Clinical Studies.)
`
`The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
`increased risk of developing probable dementia in postmenopausal women 65 years of
`age or older during 4 years of treatment with oral conjugated estrogens plus
`medroxyprogesterone acetate relative to placebo. It is unknown whether this finding
`applies to younger postmenopausal women or to women taking estrogen alone therapy.
`(See CLINICAL PHARMACOLOGY, Clinical Studies.)
`
`Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other
`combinations and dosage forms of estrogens and progestins were not studied in the WHI
`clinical trials and, in the absence of comparable data, these risks should be assumed to be
`similar. Because of these risks, estrogens with or without progestins should be prescribed
`at the lowest effective doses and for the shortest duration consistent with treatment goals
`and risks for the individual woman.
`
`0009 
`
`

`

`2
`
`DESCRIPTION
`
`Menostar™, estradiol transdermal system, is designed to provide nominal in vivo delivery
`of 14 meg 17P-estradiol per day continuously upon application to intact skin. The period
`of use is 7 days. The transdermal system has a contact surface area of 3.25 cm^, and
`contains 1.0 mg of estradiol USP.
`,
`
`Estradiol USP (17[3-estradiol) is a white, crystalline powder, chemically described as
`estra-l,3,5(10)-triene-3,17P-dioL It has an empirical formula of Cig H24 O2 and
`molecular weight of 272.39. The structural formula is:
`
`H3C
`
`OH
`H
`lull
`
`Or H
`
`m
`
`The Menostar™ transdermal system comprises three layers. Proceeding from the visible
`surface toward the surface attached to the skin, these layers are (1) a translucent
`polyethylene film, and (2) an acrylate adhesive matrix containing estradiol USP. A
`protective liner (3) of siliconized or fluoropolymer-coated polyester film is attached to
`the adhesive surface and must be removed before the transdermal system can be used.
`
`I
`
`(1) Him Bacfclno
`(2) Drug/Adlieslve Layer
`.
`(3) PiotBcttvc Liner
`The active component of the transdermal system is 17p-estradiol. The remaining
`components of the transdermal system (acrylate copolymer adhesive, fatty acid esters,
`and polyethylene backing) are pharmacologically inactive.
`
`CLINICAL PHARMACOLOGY
`
`The Menostar™ transdermal system provides systemic estrogen therapy by releasing
`17p-estradiol, the major estrogenic hormone secreted by the human ovary. .
`
`Endogenous estrogens are largely responsible for the development and maintenance of
`the female reproductive system and secondary sexual characteristics. Although
`circulating estrogens exist in a dynamic equilibrium of metabolic interconversions,
`estradiol is the principal intracellular human estrogen and is substantially more potent
`than its metabolites, estrone and estriol, at the receptor level.
`
`0010
`
`

`

`3
`
`The pritnaiy source of estrogen in Qormally cycling adult women is the ovarian follicle,
`which secretes 70 to 500 meg of estradiol daily, depending on the phase of the menstrual
`cycle. After menopause, most endogenous estrogen is produced by conversion of
`androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus,
`estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating
`estrogens in postmenopausal women.
`
`Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To
`date, two estrogen receptors have been identified. These vary in proportion from tissue to
`tissue.
`
`Circulating estrogens modulate the pituitary secretion of (he gonadotropins, luteinizing
`hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback
`mechanism. Estrogens act to reduce the elevated levels of these hormones seen in
`postmenopausal women.
`
`The decline of ovarian estrogen production that accompanies menopause or
`oophorectomy results in the acceleration of bone loss and bone resorption. Bone
`resorption is increased more than bone formation especially in the early years of
`menopause where bone loss is the greatest. In some women, these changes will
`eventually lead to decreased bone mass, osteoporosis and increased risk for fractures,
`particularly that of the spine, hip, and wrist. Vertebral fractures are the most common
`type of osteoporotic fracture in postmenopausal women.
`Postmenopausal women with low scrum estradiol concentrations and high serum
`concentrations of sex hormone-binding globulin (SHBG) have an increased risk of hip
`and vertebral fractures. Postmenopausal estrogen therapy decreases bone resorption,
`helping to reestablish balance between resorption and formation. This effect appears to be
`effective for as long as treatment is continued.
`
`PHARMACOKINETICS
`
`The bioavailability of estradiol following application of a Menostar™ transdermal
`system, relative to that of a transdermal system delivering 25 meg/day, was investigated
`in 18 healthy postmenopausal women mean age 66 years (range 60-80 years). The mean
`serum estradiol concentrations upon administration of the two patches to the lower
`abdomen are shown in Figure 1. Transdermal administration of Menostar™ produced
`geometric mean serum concentration (Cavg) of estradiol of 13.7 pg/mL. No patches
`failed to adhere during the one week application period of both transdermal systems.
`- Following application of the Menostar™ transdermal system to the abdomen, it is
`estimated to provide an average nominal in-vivo daily delivery of 14 meg estradiol/day.
`
`Absorption
`The Menostar™ transdermal delivery system continuously releases estradiol which is
`transported across intact skin leading to sustained circulating levels of estradiol during a
`7-day treatment period. The systemic availability of estradiol after transdermal
`
`0011
`
`

`

`4
`
`administration is about 20 times higher than that after oral administration. This difference is
`due to the absence of first pass metabolism when estradiol is given by the transdermal route.
`
`Figure 1
`
`Mean Uncorrected Serum 17 ^-Estradiol Concentrations vs. Time Profile Following
`Application of Menostar™ and Climara9 6.5 cniz Transdermal System
`
`40
`
`E S, 30
`cn
`CL
`c
`o
`"ro
`c 20
`QJ
`O
`c
`o
`O
`o
`^ 10 i
`is
`U)
`LU
`E
`2 <v
`
`C/J
`
`o
`
`*
`
`TM
`14 meg/day
`Menostar
`Climara 6. 5 cm3 25 meg/day
`
`"V
`
`V
`1
`
`A
`I \ J \
`I
`r
`/
`7
`I
`/
`I
`I
`
`0
`
`12 24 36 48 60 72 84 96 108 120 132 144 156 168 180
`Time (h)
`
`0012 
`
`

`

`5
`
`Table 1 provides a summary of estradiol pharmacokinetic parameters determined during
`evaluation of Menostar™ using baseline uncorrected serum concentrations.
`
`Table 1. Summary of Estradiol Pharmacokinetic Parameters (Abdomen Application)
`
`Product
`
`Estradiol
`
`AUG
`
`Cmax Cavg
`
`Tmax
`
`Cmin
`
`Daily
`Delivery
`Rate,
`meg/day
`
`(0-tlast)
`
`pg/mL pg/mL b
`
`pg/mL
`
`pg.h/mL
`
`Menostar™
`
`Climara® 6.5 cm2
`
`14
`
`25
`
`2296
`
`4151
`
`20.6
`
`37.2
`
`13.7
`
`24.7
`
`42
`
`42
`
`12.6
`
`20.4
`
`Pharmacokinetic parameters arc expressed in geometeric means except for the tmax which represents the
`median estimate and the Cmin which is expressed as the arithmetic mean.
`
`The estimated estradiol daily delivery rate for Climara® 6.5 cm2 is quoted from the
`Climara® labeling.
`
`Distribution
`The distribution of exogenous estrogens is similar to that of endogenous estrogens.
`Estrogens are widely distributed in die body and are generally found in higher
`concentrations in the sex hormone target organs. Estrogens circulate in the blood largely
`bound to sex hormone binding globulin (SHBG) and albumin. In the clinical study with
`208 patients on Menostar™, SHBG concentration (mean A SD) remained essentially
`unchanged over the 2 year period (baseline 45.1 ± 20.1 nmol/L, 24 month visit 46.4 ±
`20.9 nmol/L).
`
`Metabolism
`Exogenous estrogens are metabolized in the same manner as endogenous estrogens.
`Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions.
`These transformations take place mainly in the liver. Estradiol is converted reversibly to
`estrone, and both can be converted to estriol, which is the major urinary metabolite.
`Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide
`conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis
`in the gut followed by reabsoiption. In postmenopausal women, a significant proportion
`of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which
`serves as a circulating reservoir for the formation of more active estrogens.
`
`Excretion
`Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate
`conjugates.
`
`Special Populations:
`
`0013 
`
`

`

`6
`
`Geriatric: The efficacy and safety of Menostar™ has been studied in women between 60
`and 80 years of age, with approximately half over 65 years old.
`
`Pediatric: No pharmacokinetic study for Menostar™ has been conducted in a pediatric
`population.
`
`Gender: Menostar™ is indicated for use in postmenopausal women only.
`
`Race: No studies were done to determine the effect of race on the pharmacokinetics of
`Menostar™.
`
`Patients with Renal Impairment: Total estradiol serum levels are higher in
`postmenopausal women with end stage renal disease (ESRD) receiving maintenance
`hemodialysis than in normal subjects at baseline and following oral doses of estradiol
`Therefore, conventional transdermal estradiol doses used in individuals with normal renal
`function may be excessive for postmenopausal women with ESRD receiving maintenance
`hemodialysis.
`
`Patients with Hepatic Impairment: Estrogens may be poorly metabolized in patients with
`impaired liver function and should be administered with caution.
`
`Drug Interactions
`In vitro and in vivo studies have shown that estrogens are metabolized partially by
`cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may
`affect estrogen drug metabolism. Inducers of CYP3 A4 such as St. John's Wort
`preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may
`reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic
`effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3 A4 such as
`eiythromycm, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice
`may increase plasma concentrations of estrogens and may result in side effects.
`
`Adhesion
`In a Menostar pharmacokinetic study with 18 postmenopausal women, no patches failed
`to adhere during the one week application period
`
`Clinical Studies
`The efficacy of Menostar™ in the prevention of postmenopausal osteoporosis was
`investigated in a 2-year double blind, placebo-controlled, multicenter study in the United
`States. A total of 417 postmenopausal women, 60 to 80 years old, with an intact uterus
`were enrolled in the study. AH patients received supplemental calcium and vitamin D.
`
`Menostar™ produced larger increases in bone mass than placebo as reflected by dual-
`energy x-ray absorptiometric (DEXA) measurements of hip and lumbar spine BMD. The
`changes in BMD from baseline were statistically significantly (p <0.001) greater during
`
`0014 
`
`

`

`7
`
`treatment with Mcnostar™ than during treatment with placebo for hip and spine after 1
`and 2 years.
`
`At lumbar spine Menostar™ increased BMD by 2.3% after 1 year and 3.0% after 2 years
`compared with a 0.5% increase after 1 and 2 years of treatment with placebo. At the hip
`Menostar™ increased BMD by 0.90% after one year and 0.84% after two years
`compared with a mean decrease of 0.22% after I year and 0.71% after 2 years of placebo
`treatment (see Table 2 below).
`
`Table 2. Mean Percent BMD Change from Baseline in Lumbar Spine and Total Hip
`{Full Analysis Set)
`
`Lumbar spine
`Time points Menostar™
`Placebo
`N = 209
`N = 208 ,
`n = 189
`n= 186
`+2.29
`+0.51
`
`12-month
`Endpoint
`
`Total hip
`p-value Time points Menostar™ Placebo p-value
`N = 208
`N = 209
`n= 189
`n = 184
`+0.90
`-0.22
`
`<0.001
`
`12-month
`Endpoint
`
`<0.001
`
`n= 189
`+2.99
`
`n= 186
`+0.54
`
`< 0.001
`
`24-ni0nth
`24-month
`Endpoint
`Endpoint
`N ~ total number of patients; n = number of patients with data available for each variable
`
`n = l « 9
`+0.84
`
`n = 185
`-0.71
`
`<0.001
`
`The BMD data of the study were analyzed according to baseline estradiol levels of the
`patients. Overall, estimated treatment effects on lumbar spine and total hip BMD after 2
`years were approximately twice as large in the subgroup with baseline estradiol levels < 5
`pg/mL than in the subgroup with baseline estradiol levels > 5.0 pg/mL [Tabic 3].
`
`Table 3. Mean percent change in lumbar spine and total hip BMD at 24 months by subgroups of
`baseline estradiol level (< S pgfaiL, ^ S pg/mL)
`Lumbar spine
`Placebo
`Menostar™
`
`Treatment
`difference
`
`Menostar™
`
`Total hip
`Placebo
`
`Treatment
`difference
`
`Baseline
`estradiol
`levels
`< SpgftnL
`
`£ 5 pg/mL
`
`n= 101
`+3.50
`
`^**91
`+0.29
`
`3.21
`(p< 0.001)"
`
`n = 88
`+2.40
`
`n- 89
`+0.81
`
`1.59
`(p = 0.002)
`number of patients with data available for each variable
`
`n •=
`
`n= 101
`+1.04
`
`n = 88
`+0.61
`
`n= 96
`-1.09
`
`ii=89
`-0.31
`
`2.13
`(p< 0.001)
`
`0.92
`Cp = 0.045)
`
`Menostar™ therapy also resulted in consistent, statistically significant suppression of
`bone turnover, as reflected by changes in serum and urine markers of bone formation
`(osteocalcin and bone-specific alkaline phosphatase) and bone resorption
`
`0015 
`
`

`

`8
`
`(carboxyterminal telopeptide of type 1 collagen (ICTP) and the urinary deoxypiyridoline/
`creatinine ratio).
`
`Women's Health Initiative Studies
`The Women's Health Initiative (WHI) enrolled a total of 27,000 predominantly healthy
`postmenopausal women to assess the risks and benefits of either the use of 0.625 mg
`conjugated estrogens (CE) per day alone or the use of0.625 mg conjugated estrogens
`plus 2.5 mg medroxyprogesterone acetate (MPA) per day compared to placebo in the
`prevention of certain chronic diseases. The primary endpoint was the incidence of
`coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with
`invasive breast cancer as the primary adverse outcome studied. A "global index" included
`the earliest occurrence of CHD, invasive breast cancer, stroke, pulmonary embolism
`(PB), endometrial cancer, colorectal cancer, hip fixture, or death due to other cause. The
`study did not evaluate the effects of CE or CE/MPA on menopausal symptoms.
`
`The CE/MPA substudy was stopped early because, according to the predefined stopping
`rule, the increased risk of breast cancer and cardiovascular events exceeded the specified
`benefits included in the "global index." Results of the CE/MPA substudy, which included
`16,608 women (average age of 63 years, range 50 to 79; 83.9% White, 6.5% Black, 5.5%
`Hispanic), after an average follow-up of 5.2 years are presented in Table 5 below:
`
`Table 5 RELATIVE AND ABSOLUTE RISK SEEN IN THE CE/MPA SUBSTUDY OF
`WHI"
`Event'
`
`Placebo
`n = 8102
`
`CE/MPA
`n = 8506
`
`Relative Risk
`CE/MPA vs placebo
`at 5.2 Years
`(95% CI*)
`
`Absolute Risk per 10,000 Person-years
`
`1.29(1.02-1.63)
`1.32 (1.02-1.72)
`1.18(0.70-1.97)
`1.26 (1.00-1.59)
`1.41 (1.07-1.85)
`2.13(1.39-3.25)
`0.63 (0.43-0.92)
`0.83 (0.47-1.47)
`0.66 (0.45-0.98)
`0.92(0.74-1.14)
`
`30
`23
`6
`30
`21
`8
`16
`6
`15
`40
`
`151
`13
`15
`170
`
`CHD events
`Non-fatal MI
`CHD death
`Invasive breast cancer11
`Stroke
`Pulmonary embolism
`Colorectal cancer
`Endometrial cancer
`Hip fracture
`Death due to causes other than the
`events above
`Global Index"
`1.15(1.03-1.28)
`Deep vein thrombosis7
`2.07 (1.49-2.87)
`0.66 (0.44-0.98)
`Vertebral fractures
`0.77 (0.69-0.86)
`Other osteoporotic fractures
`'adapted from JAMA, 2002; 288:321-333
`b includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer
`ca subset of the events was combined in a "global index", defined as the earliest occurrence of CHD events,
`invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or
`death due to other causes
`'not included in Global Index.
`* nominal confidence intervals unadjusted for multiple looks and multiple comparisons
`
`37
`30
`7
`38
`29
`16
`10
`5
`10
`37
`
`170
`26
`9
`131
`
`0016 
`
`

`

`9
`
`For those outcomes included in the "global index," the absolute excess risks per 10,000
`women-years in the group treated with CE/MPA were 7 more CHD events, 8 more
`strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions
`per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The
`absolute excess risk of events included in the "global index" was 19 per 10,000 women-
`years. There was no difference between the groups in terms of all-cause mortality. (See
`BOXED WARNINGS, WARNINGS, and PRECAUTIONS.)
`
`Women's Health Initiative Memory Study
`The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, enrolled
`4,532 predominantly postmenopausal women 65 years of age and older (47% were age
`65 to 69 years, 35% were 70 to 74 years, and 18% were 75 years of age and older) to
`evaluate the effects of CE/MPA (0.625 mg conjugated estrogens plus 2.5 mg
`medroxyprogesterone acetate) on the incidence of probable dementia (primary outcome)
`compared with placebo.
`
`After an average follow-up of 4 years, 40 women in the estrogen/progestin group (45 per
`10, 000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were
`diagnosed with probable dementia. The relative risk of probable dementia in the hormone
`therapy group was 2.05 (95% CI, 1.21 to 3.48) compared to placebo. Differences between
`groups became apparent in the first year of treatment. It is unknown whether these
`findings apply to younger postmenopausal women. (See BOXED WARNINGS and
`WARNINGS, Dementia.)
`
`INDICATIONS AND USAGE
`
`Menostar™ is indicated for the prevention of postmenopausal osteoporosis. Therapy
`should be considered only for women at significant risk of osteoporosis. Non-estrogen
`medications should be carefully considered.
`
`The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing
`exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic
`therapy. Postmenopausal women require an average of 1500mg/day of elemental
`calcium. Therefore, when not contraindicated, calcium supplementation may be helpful
`for women with suboptimal dietary intake. Vitamin D supplementation of 400-800
`lU/day may also be required to ensure adequate daily intake in postmenopausal women.
`
`Risk factors for osteoporosis include low bone mineral density, low estrogen levels,
`family history of osteoporosis, previous fracture, small frame (low BMI), light skin color,
`smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment
`serum estradiol (see Table 3), and can be assessed during treatment by measuring
`biochemical markers of bone formation/resorption, and/or bone mineral density.
`
`Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss.
`Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose
`estrogen therapy was begun within a few years of menopause, compared to women taking
`
`0017 
`
`

`

`10
`
`calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of
`vertebral fractures. Even when started as late as 6 years after menopause, estrogen
`reduces further loss of bone mass for as long as treatment is continued. When estrogen
`therapy is discontinued, bone mass declines at a rate comparable to the immediate
`postmenopausal period.
`
`Data from the Women's Health Initiative study showed that use of estrogen (dose
`equivalent to 0.625 CE) resulted in about 6 less hip fractures per 10,000 women/years,
`compared to use of placebo (risk ratio about 0.6).
`
`CONTRAINDICATIONS
`
`Menostar™ should not be used in women with any of the following conditions:
`1. Undiagnosed abnormal genital bleeding.
`2. Known, suspected, or histoiy of cancer of the breast.
`3. Known or suspected estrogen-dependent neoplasia.
`4. Active deep vein thrombosis, pulmonary embolism or a history of these conditions.
`5. Active or recent (e.g. within the past year) arterial thromboembolic disease (e.g.,
`stroke, myocardial infarction).
`6. Liver dysfunction or disease.
`7. Menostar™ should not be used in patients with known hypersensitivity to its
`ingredients.
`.
`8. Known or suspected pregnancy. There is no indication for Menostar™ in pregnancy.
`There appears to be little or no increased risk of birth defects in children bom to
`women who have used estrogens and progestins from oral contraceptives
`inadvertently during early pregnancy (See PRECAUTIONS.)
`
`WARNINGS
`
`See BOXED WARNINGS.
`
`Cardiovascular disorders.
`1.
`Estrogen and estrogen/progestin therapy have been associated with an increased risk of
`cardiovascular events such as myocardial infarction and stroke, as well as venous
`thrombosis and pulmonary embolism (venous thromboembolism or VTE). Should any of
`these occur or be suspected, estrogens should be discontinued immediately.
`
`Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco
`use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal
`history or family history of VTE, obesity, and systemic lupus erythematosus) should be
`managed appropriately.
`
`a. Coronary heart disease and stroke
`In the Women's Health Initiative (WHI) study, an increase in the number of myocardial
`infarctions and strokes has been observed in womeb receiving CE compared to placebo.
`
`0018 
`
`

`

`1 1
`
`These observations are preliminary (See CLINICAL PHARMACOLOGY, Clinical
`Studies.)
`
`In the CE/MPA substudy of WHI an increased risk of coronary heart disease (CHD)
`events (defined as non-fatal myocardial infarction and CHD death) was observed in
`women receiving CE/MPA compared to women receiving placebo (37 vs. 30 per 10,000
`women years). The increase in risk was observed in year one and persisted.
`
`In the same substudy of WHI, an increased risk of stroke was observed in women
`receiving CE/MPA compared to women receiving placebo (29 vs. 21 per 10,000 women-
`years). The increase in risk was observed after the first year and persisted.
`
`In postmenopausal women with documented heart disease
`(n = 2,763, average age 66.7 years) a controlled clinical trial of secondary prevention of
`cardiovascular disease (Heart and Esfrogen/Progestin Replacement Study; HERS)
`treatment with CE/MPA (0.625mg/2.5mg per day) demonstrated no cardiovascular
`benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not
`reduce the overall rate of CHD events in postmenopausal women with established
`coronary heart disease. There were more CHD events in the CE/MPA-treated group than
`in the placebo group in year 1, but not during the subsequent years. Two thousand three
`hundred and twenty one women from the original HERS trial agreed to participate in an
`open label extension of HERS, HERS II. Average follow-up in HERS II was an
`additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were
`comparable among women in the CE/MPA group and the placebo group in HERS, HERS
`11, and overall.
`
`Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used
`to treat cancer of the prostate and breast, have been shown in a large prospective clinical
`trial in men to increase the risks of nonfatal myocardial infarction, pulmonary embolism,
`and thrombophlebitis.
`
`b